These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31975354)

  • 101. New Paradigms of Extended Thromboprophylaxis in Medically Ill Patients.
    MacDougall K; Spyropoulos AC
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32252423
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease.
    Weir MR; Ashton V; Moore KT; Shrivastava S; Peterson ED; Ammann EM
    Am Heart J; 2020 May; 223():3-11. PubMed ID: 32112872
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Rivaroxaban in Peripheral Artery Disease after Revascularization.
    Bonaca MP; Bauersachs RM; Anand SS; Debus ES; Nehler MR; Patel MR; Fanelli F; Capell WH; Diao L; Jaeger N; Hess CN; Pap AF; Kittelson JM; Gudz I; Mátyás L; Krievins DK; Diaz R; Brodmann M; Muehlhofer E; Haskell LP; Berkowitz SD; Hiatt WR
    N Engl J Med; 2020 May; 382(21):1994-2004. PubMed ID: 32222135
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety.
    Hiatt WR; Bonaca MP; Patel MR; Nehler MR; Debus ES; Anand SS; Capell WH; Brackin T; Jaeger N; Hess CN; Pap AF; Berkowitz SD; Muehlhofer E; Haskell L; Brasil D; Madaric J; Sillesen H; Szalay D; Bauersachs R
    Circulation; 2020 Dec; 142(23):2219-2230. PubMed ID: 33138628
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Identification and Outcomes of Hospitalized Medically Ill Patients Who Are Candidates for Extended Duration Thromboprophylaxis.
    Coleman CI; Piazza G; Ashton V; Bunz TJ; Spyropoulos AC
    TH Open; 2020 Oct; 4(4):e344-e350. PubMed ID: 33145475
    [No Abstract]   [Full Text] [Related]  

  • 106. Cancer-associated venous thromboembolism: Treatment and prevention with rivaroxaban.
    Bauersachs R; Khorana AA; Lee AYY; Soff G
    Res Pract Thromb Haemost; 2020 May; 4(4):532-549. PubMed ID: 32548552
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery.
    Samama CM; Laporte S; Rosencher N; Girard P; Llau J; Mouret P; Fisher W; Martínez-Martín J; Duverger D; Deygas B; Presles E; Cucherat M; Mismetti P;
    N Engl J Med; 2020 May; 382(20):1916-1925. PubMed ID: 32223113
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in orthopaedic trauma patients: A patient-centered randomized controlled trial.
    Haac BE; O'Hara NN; Manson TT; Slobogean GP; Castillo RC; O'Toole RV; Stein DM;
    PLoS One; 2020; 15(8):e0235628. PubMed ID: 32745092
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve.
    Guimarães HP; Lopes RD; de Barros E Silva PGM; Liporace IL; Sampaio RO; Tarasoutchi F; Hoffmann-Filho CR; de Lemos Soares Patriota R; Leiria TLL; Lamprea D; Precoma DB; Atik FA; Silveira FS; Farias FR; Barreto DO; Almeida AP; Zilli AC; de Souza Neto JD; Cavalcante MA; Figueira FAMS; Kojima FCS; Damiani L; Santos RHN; Valeis N; Campos VB; Saraiva JFK; Fonseca FH; Pinto IM; Magalhães CC; Ferreira JFM; Alexander JH; Pavanello R; Cavalcanti AB; Berwanger O;
    N Engl J Med; 2020 Nov; 383(22):2117-2126. PubMed ID: 33196155
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis.
    Spyropoulos AC; Lipardi C; Xu J; Peluso C; Spiro TE; De Sanctis Y; Barnathan ES; Raskob GE
    TH Open; 2020 Jan; 4(1):e59-e65. PubMed ID: 32190813
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial.
    Guntupalli SR; Brennecke A; Behbakht K; Tayebnejad A; Breed CA; Babayan LM; Cheng G; Ramzan AA; Wheeler LJ; Corr BR; Lefkowits C; Sheeder J; Matsuo K; Flink D
    JAMA Netw Open; 2020 Jun; 3(6):e207410. PubMed ID: 32589230
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study.
    Vadhan-Raj S; McNamara MG; Venerito M; Riess H; O'Reilly EM; Overman MJ; Zhou X; Vijapurkar U; Kaul S; Wildgoose P; Khorana AA
    Cancer Med; 2020 Sep; 9(17):6196-6204. PubMed ID: 32663379
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older.
    Ageno W; Lopes RD; Goldin M; Yusen RD; Albers GW; Elliott GC; Halperin JL; Hiatt WR; Maynard G; Steg PG; Weitz JI; Suh E; Lu W; Barnathan ES; Raskob GE; Spyropoulos AC
    J Thromb Haemost; 2021 Nov; 19(11):2772-2780. PubMed ID: 34314574
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism.
    Solms A; Willmann S; Reinecke I; Spiro TE; Peters G; Weitz JI; Mueck W; Garmann D; Schmidt S; Zhang L; Fox KAA; Berkowitz SD
    J Thromb Thrombolysis; 2020 Jul; 50(1):1-11. PubMed ID: 32323191
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism.
    Reinecke I; Solms A; Willmann S; Spiro TE; Peters G; Weitz JI; Mueck W; Garmann D; Schmidt S; Zhang L; Fox KAA; Berkowitz SD
    J Thromb Thrombolysis; 2020 Jul; 50(1):12-19. PubMed ID: 32323190
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative.
    Barkoudah E; Piazza G; Hecht TEH; Grant P; Deitelzweig S; Fang MC; Fanikos J; Kao CK; Barnes GD; Chen T; Ramishvili T; Schnipper JL; Goldstein JN; Ruff CT; Kaatz S; Schwartz A; Connors JM; Goldhaber SZ
    Am J Med; 2020 May; 133 Suppl 1():1-27. PubMed ID: 32362349
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study.
    Capell WH; Barnathan ES; Piazza G; Spyropoulos AC; Hsia J; Bull S; Lipardi C; Sugarmann C; Suh E; Rao JP; Hiatt WR; Bonaca MP
    Am Heart J; 2021 May; 235():12-23. PubMed ID: 33577800
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Current Opinion on the use of Direct Oral Anticoagulants for the Prophylaxis of Venous Thromboembolism among Medical Inpatients.
    Lee JJ; Memar Montazerin S; Shojaei F; Chi G
    Ther Clin Risk Manag; 2021; 17():471-487. PubMed ID: 34079269
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials.
    Spyropoulos AC; Raskob GE; Cohen AT; Ageno W; Weitz JI; Spiro TE; Lu W; Lipardi C; Albers GW; Elliott CG; Halperin JL; Hiatt WR; Maynard G; Steg PG; Sugarmann C; Barnathan ES
    Circulation; 2022 May; 145(19):1471-1479. PubMed ID: 35389229
    [TBL] [Abstract][Full Text] [Related]  

  • 120. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review.
    Bikdeli B; Madhavan MV; Jimenez D; Chuich T; Dreyfus I; Driggin E; Nigoghossian C; Ageno W; Madjid M; Guo Y; Tang LV; Hu Y; Giri J; Cushman M; Quéré I; Dimakakos EP; Gibson CM; Lippi G; Favaloro EJ; Fareed J; Caprini JA; Tafur AJ; Burton JR; Francese DP; Wang EY; Falanga A; McLintock C; Hunt BJ; Spyropoulos AC; Barnes GD; Eikelboom JW; Weinberg I; Schulman S; Carrier M; Piazza G; Beckman JA; Steg PG; Stone GW; Rosenkranz S; Goldhaber SZ; Parikh SA; Monreal M; Krumholz HM; Konstantinides SV; Weitz JI; Lip GYH;
    J Am Coll Cardiol; 2020 Jun; 75(23):2950-2973. PubMed ID: 32311448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.